293 related articles for article (PubMed ID: 11137086)
21. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
[TBL] [Abstract][Full Text] [Related]
22. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ
Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115
[TBL] [Abstract][Full Text] [Related]
23. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
Aoki S; Ikeda K; Yamamura M; Kojo S
Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
[TBL] [Abstract][Full Text] [Related]
24. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
25. Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta.
Kagota S; Yamaguchi Y; Nakamura K; Kunitomo M
Clin Exp Pharmacol Physiol; 2000; 27(5-6):401-5. PubMed ID: 10831243
[TBL] [Abstract][Full Text] [Related]
26. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
27. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.
Kano H; Hayashi T; Sumi D; Esaki T; Asai Y; Thakur NK; Jayachandran M; Iguchi A
Biochem Biophys Res Commun; 1999 Jun; 259(2):414-9. PubMed ID: 10362523
[TBL] [Abstract][Full Text] [Related]
28. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation.
Suzumura K; Odawara A; Yasuhara M; Tanaka K; Narita H; Suzuki T
Biol Pharm Bull; 1999 Sep; 22(9):971-4. PubMed ID: 10513623
[TBL] [Abstract][Full Text] [Related]
29. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Hussein O; Schlezinger S; Rosenblat M; Keidar S; Aviram M
Atherosclerosis; 1997 Jan; 128(1):11-8. PubMed ID: 9051193
[TBL] [Abstract][Full Text] [Related]
30. Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice.
Gervais M; Pons S; Nicoletti A; Cosson C; Giudicelli JF; Richer C
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):183-9. PubMed ID: 12588757
[TBL] [Abstract][Full Text] [Related]
31. [Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Jorge PA; Almeida EA; Ozaki MR; Jorge M; Carneiro A
Arq Bras Cardiol; 2005 Apr; 84(4):314-9. PubMed ID: 15880205
[TBL] [Abstract][Full Text] [Related]
32. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
33. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
Ito T; Ikeda U; Shimpo M; Ohki R; Takahashi M; Yamamoto K; Shimada K
Cardiovasc Drugs Ther; 2002 Mar; 16(2):121-6. PubMed ID: 12090904
[TBL] [Abstract][Full Text] [Related]
34. Comparison of lycopene and fluvastatin effects on atherosclerosis induced by a high-fat diet in rabbits.
Hu MY; Li YL; Jiang CH; Liu ZQ; Qu SL; Huang YM
Nutrition; 2008 Oct; 24(10):1030-8. PubMed ID: 18585898
[TBL] [Abstract][Full Text] [Related]
35. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Yasunari K; Maeda K; Minami M; Yoshikawa J
Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
[TBL] [Abstract][Full Text] [Related]
36. Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum.
Obata T; Yamanaka Y
Brain Res; 2000 Mar; 860(1-2):166-9. PubMed ID: 10727637
[TBL] [Abstract][Full Text] [Related]
37. Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits.
Keaney JF; Gaziano JM; Xu A; Frei B; Curran-Celentano J; Shwaery GT; Loscalzo J; Vita JA
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11880-4. PubMed ID: 8265642
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
39. Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin.
Prochnau D; Rödel J; Prager K; Kuersten D; Heller R; Straube E; Figulla HR
Acta Microbiol Immunol Hung; 2010 Jun; 57(2):147-55. PubMed ID: 20587387
[TBL] [Abstract][Full Text] [Related]
40. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels.
Schneider MP; Schmidt BM; John S; Schmieder RE
J Hypertens; 2011 Sep; 29(9):1757-64. PubMed ID: 21799442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
